Patents by Inventor Luigi Piero Stasi

Luigi Piero Stasi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds active towards nuclear receptors
    Patent number: 11780843
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: October 10, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Luigi Piero Stasi, Montserrat Erra Solà, Joan Taltavull Moll, Paul Robert Eastwood
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20230271937
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: May 5, 2023
    Publication date: August 31, 2023
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • Compounds active towards nuclear receptors
    Patent number: 11685727
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: June 27, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • Compounds active towards nuclear receptors
    Patent number: 11613532
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: March 28, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Luigi Piero Stasi
  • HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)
    Publication number: 20230076506
    Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.
    Type: Application
    Filed: December 11, 2020
    Publication date: March 9, 2023
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Agnieszka Justyna GIBAS, Anna RAJDA, Charles-Henry FABRITIUS, Adam RADZIMIERSKI, Tushar Ravindra MAHAJAN, Marcin Wojciech LES, Karol ZUCHOWICZ, Marek WRONOWSKI, David Jörg SYNAK, Sundara Raghuram TANGIRALA
  • FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)
    Publication number: 20230055741
    Abstract: The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).
    Type: Application
    Filed: December 11, 2020
    Publication date: February 23, 2023
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Agnieszka Justyna GIBAS, Anna RAJDA, Charles-Henry FABRITIUS, Adam RADZIMIERSKI, Tushar Ravindra MAHAJAN, Marcin Wojciech LES, Karol ZUCHOWICZ, Marek WRONOWSKI, David Jörg SYNAK, Sundara Raghuram TANGIRALA
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20220363683
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: March 31, 2021
    Publication date: November 17, 2022
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Luigi Piero Stasi, Montserrat Erra Solà, Joan Taltavull Moll, Paul Robert Eastwood
  • Compounds active towards nuclear receptors
    Patent number: 11447479
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: September 20, 2022
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi
  • NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)
    Publication number: 20220251082
    Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Monika Patrycja DOBRZANSKA, Grzegorz Witold TOPOLNICKI, Agnieszka Justyna GIBAS, Anna RAJDA, Sylwia SUDOL, Karolina Maria GLUZA, Charles-Henry FABRITIUS
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20220098182
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: March 31, 2021
    Publication date: March 31, 2022
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Luigi Piero Stasi
  • Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
    Patent number: 11254681
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: February 22, 2022
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Niels Grøn Nørager, Ian Sarvary, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20210188828
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20210188807
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
    Patent number: 10975081
    Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 13, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Yun Jin, Qian Liu, Feng Ren, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Hailong Wang, Weiqiang Xing, Yang Zhan, Baowei Zhao
  • OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES
    Publication number: 20200392140
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: May 11, 2020
    Publication date: December 17, 2020
    Inventors: Sanne Schrøder Glad, Niels Grøn Nørager, Ian Sarvary, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
    Patent number: 10689383
    Abstract: Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 23, 2020
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Kim Birkebæk Jensen, Niels Grøn Nørager, Ian Sarvary, Mikkel Vestergaard, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
    Patent number: 10683293
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 16, 2020
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Niels Grøn Nørager, Ian Sarvary, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • LRRK2 inhibitors for the treatment of Parkinson's disease
    Patent number: 10618901
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: April 14, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge
  • COMPOUNDS
    Publication number: 20200079777
    Abstract: Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 22, 2016
    Publication date: March 12, 2020
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiao DING, Yun JIN, Qian LIU, Feng REN, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Hailong WANG, Weiqiang XING, Yang ZHAN, Baowei ZHAO
  • COMPOUNDS
    Publication number: 20180354956
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: August 2, 2018
    Publication date: December 13, 2018
    Inventors: Xiao Ding, Qian Liu, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Baowei Zhao, Colin Michael Edge